Number of Highly Rated PDP Contracts Shrinks in 2023

Only 9% of Medicare beneficiaries who sign up for a stand-alone Prescription Drug Plan (PDP) in 2023 will be in contracts rated 4 stars or higher, compared to 42% in the 2022 plan year, CMS recently estimated based on current enrollment figures. The average star rating for stand-alone PDP plans declined to 3.25 in 2023 from 3.70 in 2022, with only two PDP contracts receiving a 5-star rating. The change in distribution is largely due to adjustments in measure scores, and “the unusual circumstance of nearly all contracts qualifying for the regulatory adjustment for extreme and uncontrollable circumstances” driven by the pandemic, which led to higher than normal 2022 Star Ratings distributions, CMS explained in a fact sheet accompanying the release of the 2023 Star Ratings.


Based on current enrollment, 53% of Cigna Corp.’s membership is estimated to be in a 4-star contract in 2023. CVS Health Corp.’s SilverScript Insurance Company, the largest PDP sponsor, will have all of its enrollees in a plan with 3.5 stars. Meanwhile, Clear Spring Health’s PDP contract, which is estimated to cover almost 300,000 enrollees, only scored 1.5 stars.


Scores for most 2023 Star Ratings measures changed only slightly compared to data from the prior year at the national level. The Statin Use in Persons With Diabetes measure saw the largest increase. Plans’ scores on two member experience measures — Rating of Drug Plan and Getting Needed Prescription Drugs — will decline in 2023.


NOTES: Analysis does not include enrollment data from contracts that were too new to be rated, or did not have enough data available to measure a star rating. For Complaints About the Plan and Members Choosing to Leave the Plan, a lower score is better. The Complaints About the Plan measure is a rate of complaints about the plan per 1,000 members.

SOURCES: CMS. DHP, AIS’s Directory of Health Plans, as of October 2022.

This infographic was reprinted from AIS Health’s biweekly publication RADAR on Drug Benefits.

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

February 3

Star Ratings Surge Could Disrupt the Market During Special Enrollment Period

August 18

National Average Part D Bid Continues Downward Trajectory, but for How Long?



Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today